Clinical Trials Logo

Acute Agitation clinical trials

View clinical trials related to Acute Agitation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03624322 Completed - Acute Agitation Clinical Trials

Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101

SNAP101
Start date: August 5, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INP105, which is an investigational drug-device combination product comprised of the drug component OLZ administered by a Precision Olfactory Delivery (POD®) nasal spray device (I231 POD® Device). The proposed indication for INP105 is the treatment of acute agitation associated with schizophrenia and bipolar I disorder.